TARE / Y-90 RADIOEMBOLIZATION
SELECTIVE INTERNAL RADIATION THERAPY

TARE, or transarterial radioembolization, also called selective internal radiation therapy or SIRT, is a procedure that delivers radiation directly into liver tumors through their blood supply. Tiny radioactive beads, usually made with Yttrium-90, are injected through a catheter into the arteries feeding the tumor, where they lodge in place and release radiation directly into the cancerous tissue over several days. 

Since the US Food and Drug Administration approved yttrium-90 radioembolization microspheres for the treatment of hepatic malignancies, selective internal radiation therapy has emerged as a validated and effective modality in this field. Because the radiation is delivered locally, it can treat the tumor with a strong dose while limiting exposure to the rest of the body.

TARE is mainly used for liver tumors that cannot be surgically removed, including primary liver cancer (hepatocellular carcinoma) and liver metastases from other cancers, particularly colorectal cancer. The NCCN clinical practice guidelines for both colon and rectal cancers list Yttrium-90 microsphere selective internal radiation as an option in highly selected individuals with chemotherapy-resistant or refractory disease and with predominant hepatic metastases. 

It has also been used in liver-dominant metastatic pancreatic cancer and in other situations where the liver is the main site of disease. Suitability depends on how much of the liver is involved, overall liver function, and whether the disease has spread significantly outside the liver.

Effectiveness varies by cancer type and how TARE is used. In primary liver cancer, a 2026 meta-analysis set out to clarify outcomes precisely because, as the researchers noted, the efficacy and safety of TARE compared to conventional treatments remain uncertain in advanced disease, reflecting that results can be mixed depending on patient selection. 

In more favorable, appropriately selected cases, results have been stronger. A study of TARE used to shrink tumors before surgery found that TARE was efficient in inducing tumor necrosis and stimulating the growth of the subsequent liver remnant, thus permitting surgery in patients who were initially not suitable to receive definitive treatment, with 76% of patients alive and disease-free at final follow-up. In colorectal cancer that has spread to the liver and stopped responding to chemotherapy, TARE improved overall survival compared with best supportive care when used as a third-line treatment.

TARE is generally not considered a stand-alone cure for advanced disease, but it has an important and sometimes curative-enabling role in specific situations. One of its clearest benefits is as a bridge to a truly curative treatment, surgery, or transplant. In one study of TARE used this way, the procedure successfully reduced tumors enough that liver resection was performed on 17 patients and liver transplantation by living donors on 8 patients out of 25 treated. 

For patients with disease too advanced for surgery, TARE is better understood as a way to control tumor growth and extend survival rather than eliminate the cancer outright. Whether TARE could open the door to a curative procedure or is being used mainly for disease control depends entirely on the individual case.

TARE is usually done in two stages. First, a planning angiogram maps the liver's blood vessels and checks how much of the injected material might travel to the lungs or other organs, an important safety step before the real treatment. During the planning phase, 3D-mapping angiographies are performed to identify suitable injection positions and ensure complete tumor coverage, followed by intra-arterial injection of technetium-99m macroaggregated albumin and subsequent SPECT/CT imaging. 

A week or so later, the actual treatment is delivered, where the radioactive microspheres are injected through a catheter into the tumor's blood supply under imaging guidance. The procedure is typically done as an outpatient or short-stay treatment, and the radiation continues working inside the tumor for several days afterward.

Most patients experience a mild, temporary set of symptoms after TARE, sometimes called post-radioembolization syndrome, including fatigue, abdominal discomfort, and low-grade fever for a few days. More serious complications are uncommon but are actively studied. One detailed review of TARE-related complications across multiple studies focused specifically on the management of postprocedural adverse events following transarterial radioembolization as an important area for ongoing clinical attention. 

In studies combining TARE with chemotherapy for liver metastases, most side effects were manageable, though some patients experienced more specific complications such as elevated bilirubin or inflammation of the gallbladder, which is why liver function and gallbladder anatomy are checked carefully before treatment.

TARE is an FDA-approved, established treatment available at major liver cancer and interventional radiology centers, though it requires specific equipment, radioactive material handling capability, and a trained multidisciplinary team, so it is concentrated in larger or specialized centers rather than every hospital. The American College of Radiology states that transarterial radioembolization may be appropriate for solitary colorectal liver metastasis and multifocal bilobar colorectal carcinoma, reflecting how its use is guided by specific clinical criteria rather than being a default option. Coverage and recommendations also vary by guideline body and indication, so confirming a center's specific experience with the patient's tumor type matters.

CancerFax helps patients and families understand whether TARE is a suitable option for their liver tumor and, where appropriate, connects them with experienced interventional radiology and oncology teams offering this treatment, whether as a primary treatment, a bridge to surgery or transplant, or part of a combination approach. 

This support can include reviewing the diagnosis, liver function, and the extent of disease in and outside the liver, arranging expert second opinions, and coordinating the practical side of accessing care, including hospital communication, documentation, translation, and travel support. Because TARE suitability depends heavily on tumor location, liver function, and overall disease spread, the first step is always a thorough case review by the treating oncology and interventional radiology team.